Illumina announced its acquisition of proteomics technology assets originally developed by SomaLogic from Standard BioTools for a deal valued up to $425 million, including upfront cash, milestones, and royalties. This acquisition strengthens Illumina's presence in the expanding proteomics market and accelerates its multiomics strategy. The purchased assets include a CLIA- and CAP-certified lab and over 250 employees tied to SomaLogic's commercial and R&D operations. Illumina and SomaLogic have collaborated on proteomics assay development for several years, and the acquisition aims to enhance biomarker discovery and disease profiling capabilities.